Combination of AURKA inhibitor and MEK inhibitor strongly enhances G1 arrest and induces synergistic antitumor effect on KRAS or BRAF mutant colon cancer cells

In colorectal cancer, RAS and BRAF are major mutation points in the RAS-MAPK signaling pathway. These gene mutations are known to be important causes of resistance to anti-EGFR antibody therapies. Recently, it has been reported that Aurora kinase A (AURKA), one of the mitotic kinases, interacts with...

Full description

Saved in:
Bibliographic Details
Main Authors: Masashi Sato, Yoshiyuki Yamamoto, Toshikazu Moriwaki, Kuniaki Fukuda, Kiichiro Tsuchiya
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Biochemistry and Biophysics Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2405580825001608
Tags: Add Tag
No Tags, Be the first to tag this record!